Expert opinion on clinical application of Cofrogliptin tablets
Expert Group on Clinical Application of Cougliptin,China
MU Yi-ming
SHAN Zhong-yan
Abstract：Dipeptidyl peptidase-4(DPP-4)inhibitors is effective,safe,and body-weight neutral.Most of them areorally administered once a day.DPP-4 inhibitor has become one of the preferred options for newly diagnosed type 2 diabetes and elderly diabetes patients.The novel ultralong-acting DPP-4 inhibitor,Cofrogliptin,is orally administered once every 2 weeks.While ensuring efficacy and safety,it can further improve compliance.This article provides suggestions on the suitable population,usage,and cautions in special populations for Cofrogliptin,in order to providing reference for clinical practice.
Keywords：type 2 diabetesexpert opiniondipeptidyl peptidase-4 inhibitorsultralong-actingCofrogliptin
Publication Date：2024-11-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 917-920 )